CAPLYTA net product sales grew to $199.2 million, representing a 51%increase over the same period in 2023Full year 2024 ...

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023Full year revenues increased 473% to $290.5 million versus ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

Recently, the work was completed by the group of Prof. Sheng Meng from the Institute of Physics, Chinese Academy of Sciences, and Beijing National ...

Recently, the work was completed by the group of Prof. Sheng Meng from the Institute of Physics, Chinese Academy of Sciences, and Beijing National Research Center for Condensed Matter Physics. By ...

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, ...

Both projects revealed unexpected deviations from the canonical mechanisms of magnetic freezing, with unexpected oscillations near the phase transition. A classical magnetic material can be understood ...

State Key Lab for Strength and Vibration of Mechanical Structures, Department of Engineering Mechanics, Xi’an Jiaotong University, Xi’an 710049, P. R. China ...

Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States ...